3XV logo

Xvivo Perfusion DB:3XV Stock Report

Last Price

€38.35

Market Cap

€1.2b

7D

-3.8%

1Y

n/a

Updated

22 Nov, 2024

Data

Company Financials +

3XV Stock Overview

A medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. More details

3XV fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance4/6
Financial Health6/6
Dividends0/6

Xvivo Perfusion AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Xvivo Perfusion
Historical stock prices
Current Share PriceSEK 38.35
52 Week HighSEK 46.80
52 Week LowSEK 30.25
Beta2.13
11 Month Change-10.29%
3 Month Change-17.26%
1 Year Changen/a
33 Year Changen/a
5 Year Changen/a
Change since IPO25.53%

Recent News & Updates

Recent updates

Shareholder Returns

3XVDE Medical EquipmentDE Market
7D-3.8%-1.0%-0.02%
1Yn/a-7.3%8.2%

Return vs Industry: Insufficient data to determine how 3XV performed against the German Medical Equipment industry.

Return vs Market: Insufficient data to determine how 3XV performed against the German Market.

Price Volatility

Is 3XV's price volatile compared to industry and market?
3XV volatility
3XV Average Weekly Movement4.7%
Medical Equipment Industry Average Movement5.5%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.9%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 3XV has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 3XV's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998161Christoffer Rosenbladwww.xvivogroup.com

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment.

Xvivo Perfusion AB (publ) Fundamentals Summary

How do Xvivo Perfusion's earnings and revenue compare to its market cap?
3XV fundamental statistics
Market cap€1.24b
Earnings (TTM)€17.76m
Revenue (TTM)€65.27m

69.6x

P/E Ratio

18.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
3XV income statement (TTM)
RevenueSEK 750.59m
Cost of RevenueSEK 192.08m
Gross ProfitSEK 558.52m
Other ExpensesSEK 354.25m
EarningsSEK 204.27m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Jan 28, 2025

Earnings per share (EPS)6.48
Gross Margin74.41%
Net Profit Margin27.21%
Debt/Equity Ratio0%

How did 3XV perform over the long term?

See historical performance and comparison